<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1929">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136053</url>
  </required_header>
  <id_info>
    <org_study_id>APB-A1-101</org_study_id>
    <nct_id>NCT05136053</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-A1 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, 2-Part, Single Ascending Dose, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-A1 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AprilBio Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AprilBio Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will be the FIH study of APB-A1. The study is intended to collect data on&#xD;
      APB-A1 in order to support further development of this compound as a useful clinical&#xD;
      candidate.&#xD;
&#xD;
      This study will establish safety and tolerability profiles for APB-A1 and will allow&#xD;
      identification of recommended dose levels and dose intervals in subsequent studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, 2-part,</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>PI and clinical staff are blinded to the treatment; however safety review of clinical laboratories including white blood cells count will be done real-time. These results may have potential to show pharmacologic effect, but treatment will not be unblinded unless needed for safety reasons.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of TEAEs</measure>
    <time_frame>16 Weeks</time_frame>
    <description>the safety and tolerability of single intravenous (IV) doses of APB A1 when administered to healthy adult subjects in Part A and Part B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>16 Weeks</time_frame>
    <description>area under the concentration time curve, from time 0 to the last observed non-zero concentration of APB-A1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>16 Weeks</time_frame>
    <description>area under the concentration time curve from time 0 extrapolated to infinity of APB-A1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC%extrap</measure>
    <time_frame>16 Weeks</time_frame>
    <description>percent of AUC0-inf extrapolated of APB-A1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>16 Weeks</time_frame>
    <description>time to maximum observed concentration of APB-A1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA detection</measure>
    <time_frame>16 Weeks</time_frame>
    <description>immunogenicity of single IV doses of APB A1 in healthy adult subjects in Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDAR (anti-KLH IgGand IgM titers).</measure>
    <time_frame>16 Weeks</time_frame>
    <description>PD effect of single IV doses of APB A1 on T cell dependent antibody response (TDAR) to KLH primary and secondary immunization in healthy adult subjects in Part B</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive APB-A1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 % Dextrose Water</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>APB-A1</intervention_name>
    <description>fusion protein developed by AprilBio</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, adult, male or female* (of non childbearing potential only), 19-60 years of&#xD;
             age, inclusive&#xD;
&#xD;
          -  Male subjects must follow protocol specified contraception guidance&#xD;
&#xD;
          -  Continuous non smoker who has not used nicotine containing products for at least 3&#xD;
             months prior to Day 1&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 and weight between 50 and 125 kg&#xD;
             (inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of alcohol or drug abuse within the past 2 years prior to Day 1.&#xD;
&#xD;
          -  History or presence of hypersensitivity or idiosyncratic reaction to the study drug or&#xD;
             related compounds (e.g., monoclonal antibodies).&#xD;
&#xD;
          -  History or presence of tuberculosis infection or positive QuantiFERON®-TB result at&#xD;
             the screening visit.&#xD;
&#xD;
          -  History of disease(s) of the immune system function.&#xD;
&#xD;
          -  Received any vaccination in the last 2 months prior to Day 1.&#xD;
&#xD;
          -  Positive results at the screening visit for human immunodeficiency virus (HIV),&#xD;
             hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
          -  Any immunosuppressing medications 2 months prior to Day 1 and throughout the study.&#xD;
&#xD;
          -  Participation in another clinical study with monoclonal antibody within 90 days or 5&#xD;
             half lives (whichever is longer) prior to Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aprilbio Co., ltd</last_name>
    <phone>+82 70 4027 7611</phone>
    <email>avbcu@aprilbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Frontage Clinical Services Inc.</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Frontage C, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

